These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26817454)

  • 1. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
    Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
    Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
    Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluctuation of Disease Severity and Quality of Life Applying Intralymphatic Immunotherapy for Patients with Seasonal Allergic Rhinitis.
    Khoshkhui M; Jabbari F; Shafiee Zargar F; Motavalli Haghi N; Ariaee N
    Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):149-157. PubMed ID: 38822510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
    Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
    Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.
    Thompson CP; Silvers S; Shapiro MA
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):311-318.e2. PubMed ID: 32407947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
    Hjalmarsson E; Hellkvist L; Karlsson A; Winquist O; Kumlien Georén S; Westin U; Cardell LO
    J Investig Allergol Clin Immunol; 2023 Oct; 33(5):362-372. PubMed ID: 37843385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
    Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
    Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.
    Powell RJ; Frew AJ; Corrigan CJ; Durham SR
    Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase.
    Hellkvist L; Hjalmarsson E; Weinfeld D; Dahl Å; Karlsson A; Westman M; Lundkvist K; Winqvist O; Georén SK; Westin U; Cardell LO
    Allergy; 2022 Mar; 77(3):883-896. PubMed ID: 34379802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Safety, Efficacy, and Compliance of Intralymphatic Immunotherapy for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis.
    Wang W; Wang X; Wang H; Wang X
    Int Arch Allergy Immunol; 2023; 184(8):754-766. PubMed ID: 37105134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
    Serrano E; Wahn HU; Didier A; Bachert C
    Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.